Ambrosia

Confirm your age

You must be over 18 to enter this website. Please enter your date of birth to continue.

By entering you confirm you are 18 or older and agree to our Terms and Privacy Policy.

Back to articles
Hormone healthCJC-1295IpamorelinSleep

CJC-1295 & Ipamorelin: A Beginner's Guide to the Combination

Published by Ambrosia In-House Council2026-11-02 3 min read
Medically reviewed by Ambrosia clinical team

CJC-1295 and ipamorelin act on two different growth hormone pathways. Here's why they're paired, what the research covers and what to discuss with your doctor.

CJC-1295 & Ipamorelin: A Beginner's Guide to the Combination

Two signals, one pathway

Your pituitary gland releases growth hormone in pulses, with much of it released during sleep. Two kinds of signal can encourage that release:

  • Growth hormone-releasing hormone (GHRH): CJC-1295 is a man-made version of this signal.
  • The ghrelin receptor: ipamorelin acts here, through a separate route.

The theory behind pairing them is that using two routes may produce a stronger pulse. Your own body is still making the growth hormone, rather than receiving it directly.

With DAC or without DAC?

This difference matters, because the best-known human study used a different form from the one in Ambrosia's cartridge.

That 2006 study tested CJC-1295 with DAC, an attachment that binds to a blood protein and extends how long the compound lasts. Its half-life was about 6 to 8 days, and it raised growth hormone for 6 days or more.

Ambrosia's cartridge contains CJC-1295 without DAC, which clears much more quickly. Results from the DAC study can't simply be applied to it.

What the research on ipamorelin shows

Ipamorelin was described in 1998 as the first selective compound of its type. In studies using rat cells, rats and pigs, it released growth hormone without raising ACTH or cortisol beyond the levels seen with GHRH. In pigs, it didn't change FSH, LH, prolactin or TSH.

These are animal results. They support the idea of selectivity, but don't prove the same in every person.

What we don't know yet

We didn't find good-quality human trials showing that this specific combination improves body composition, recovery, sleep, skin or ageing. Claims about these benefits go beyond what has been proven.

There's also no reliable week-by-week timeline. Agree with your doctor which symptoms and blood results you'll track, and when you'll review whether it's helping.

Safety

Ambrosia's product information lists these reasons not to use this combination:

  • Active cancer or a history of cancer
  • Pituitary disorders or untreated hypothyroidism
  • Pregnancy or breastfeeding

Growth hormone release can raise blood sugar. Tell your doctor if you have diabetes or pre-diabetes, or take insulin, other glucose-lowering medicines, corticosteroids or other hormone therapies.

Possible side effects include increased hunger, water retention, tingling in the hands, joint aches and changes in blood sugar.

How Ambrosia dispenses it

The cartridge contains CJC-1295 (No DAC) 5,6 mg and ipamorelin 5,6 mg in 2,4 ml. It's usually injected once a day, often in the evening. Your doctor decides whether it suits you and sets your dose.

Every Ambrosia treatment requires a prescription from a doctor who has reviewed your medical history.

This article is for educational purposes only and is not medical advice.

References

Recommended for you

Shop the products mentioned in this article — complete your intake to order.

Epithalon Cartridge
Cold chain

Epithalon Cartridge

R 2080.00 Incl. VAT

Melatonin Oral Spray
Cold chain

Melatonin Oral Spray

R 184.00 Incl. VAT

CJC-1295 (No DAC) & Ipamorelin Cartridge
Cold chain

CJC-1295 (No DAC) & Ipamorelin Cartridge

R 1424.00 Incl. VAT